David, We all make our own investment decisions
Post# of 148162
We all make our own investment decisions. Despite NP discussion of share price, our individual anxieties are immaterial to company decisions.
Cytodyn, despite leronlimab, is a nobody in the pharmaceutical world. Leronlimab needs to be proven unequivocally. Following DSMB recommendations will provide that proof. I assume there will be updates on enrollment totals, but until we get to 293, they will be a bit academic.
I, despite being deeply in the red, am vehemently opposed to any actions supporting short share price at the expense of long term prospects.
I imagine Cytodyn has the same perspective or the data would already have been unblinded.
Patience required by all. A mentor of mine always reminded that “When in a hurry, dress slowly”. Methodical will get us there.